瑞舒伐他汀改善静脉血栓患者凝血指标
一项随机临床试验纳入247例既往静脉血栓患者,随机接受瑞舒伐他汀20mg/日4周或不干预。结果显示瑞舒伐他汀使用者多种凝血因子平均水平明显下降,以FVIII:C下降最一致,提示他汀可能降低复发风险。
要点
- 瑞舒伐他汀20mg/日4周可降低既往静脉血栓患者的凝血因子水平。
- FVIII:C在瑞舒伐他汀组平均降低7.2 IU/dL,非使用者无变化。
- 特发性静脉血栓及心血管危险因素者凝血因子下降更明显。
核心结论
- 瑞舒伐他汀20mg/日可显著改善既往静脉血栓患者的凝血谱。
- 结果提示他汀治疗可能对复发静脉血栓风险患者有益。
研究设计与样本
- 随机临床试验(NCT01613794),247例既往静脉血栓患者随机接受瑞舒伐他汀20mg/日4周或不干预。
- 平均年龄58岁,62%为女性,49%为特发性静脉血栓。
主要发现
- 瑞舒伐他汀使用者所有检测凝血因子平均水平在研究结束时明显下降,非使用者几乎无变化。
- FVIII:C在瑞舒伐他汀组平均降低7.2 IU/dL(95%CI 2.9-11.5),非使用者平均差异-0.1(95%CI -3.0至2.9)。
- 年龄和性别调整后,FVIII:C变化的组间平均差异为-6.7 IU/dL(95%CI -12.0至-1.4)。
- 亚组分析显示特发性静脉血栓和心血管危险因素者凝血因子下降更明显。
临床怎么用
- 对既往静脉血栓患者,可考虑使用瑞舒伐他汀20mg/日以改善凝血指标。
- 特发性静脉血栓或合并心血管危险因素者可能获益更明显。
局限性
- 原文未报告试验的盲法、依从性及不良事件等细节。
- 随访仅4周,未评估临床复发静脉血栓终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Observational studies indicate that statins reduce the risk of recurrent venous thrombosis (VT). However, trials have not been performed and the mechanism is unknown. We aimed to determine whether statin therapy improves the coagulation profile in patients with prior VT. METHODS AND RESULTS: Randomized clinical trial (NCT01613794). Patients were randomized to rosuvastatin 20 mg/day for 4 weeks or no intervention. Blood was drawn at baseline and at end of study. The primary outcome was factor (F) VIII:C. In total, five coagulation factors were measured: FVIII:C, von Willebrand factor:Ag, FVII:C, FXI:C, and D-dimer. Among 247 randomized participants, mean age was 58 years, 62% were women and 49% had unprovoked VT. For all tested coagulation factors, mean levels were clearly decreased at end of study in rosuvastatin users, whereas they hardly differed in non-statin users. Results were most consistent for FVIII:C where mean FVIII:C levels were 7.2 IU/dL [95% CI (confidence interval) 2.9-11.5] lower in rosuvastatin users, while among non-users, no change in FVIII:C was observed (mean difference -0.1; 95% CI -3.0 to 2.9). The mean age and sex adjusted difference in FVIII:C change was -6.7 IU/dL (95% CI -12.0 to -1.4) in rosuvastatin users vs. non-users. Subgroup analyses revealed that the decrease in coagulation factors by rosuvastatin was more pronounced in participants with unprovoked VT and in those with cardiovascular risk factors. CONCLUSION: Rosuvastatin 20 mg/day substantially improved the coagulation profile among patients with prior VT. These results suggest that statin therapy might be beneficial in patients at risk of recurrent VT.
引用
- Biedermann JS, Kruip MJHA, van der Meer FJ, et al. Rosuvastatin use improves measures of coagulation in patients with venous thrombosis. Eur Heart J. 2018. PMID: 29394348. doi:10.1093/eurheartj/ehy014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。